0VF9 Stock Chart & Stats
C$0.12
C$0.00(0.00%)
At close: 4:00 PM EDT
C$0.12
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.10 - C$0.13
Previous CloseN/A
Volume0.00
Average Volume (3M)946.00
Market Cap
C$32.67M
Enterprise ValueC$136.17
Total Cash (Recent Filing)C$50.03K
Total Debt (Recent Filing)C$75.06M
Price to Earnings (P/E)―
Beta1.39
Next Earnings
Aug 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding343,916,100
10 Day Avg. Volume50
30 Day Avg. Volume946
Financial Highlights & Ratios
PEG Ratio-7.26
Price to Book (P/B)-0.23
Price to Sales (P/S)0.00
P/FCF Ratio-5.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Platform & ScienceResverlogix’s focus on epigenetic mechanisms, notably BET proteins, is a durable scientific differentiator. A platform approach can enable multiple programs and indication expansions, improving long-term partnership appeal and increasing optionality for licensing or co-development deals.
Clear Monetization PathwaysAs a clinical-stage biotech, the company’s business model centers on established industry monetization routes—partner collaborations, milestone/licensing fees and royalties, and capital raises. These channels provide structural, repeatable funding mechanisms aligned with R&D progress.
Improving Cash Outflow TrendA modest reduction in negative free cash flow from 2024 to 2025 suggests early operational stabilization. If management sustains tighter burn control, the trend can extend runway, lower near-term financing frequency, and incrementally reduce refinancing pressure over the next several quarters.
Bears Say
No Revenue, Large LossesThe company reports no revenue across recent periods while incurring sizable operating and net losses. This structural lack of operating income means ongoing R&D investments must be funded externally, leaving execution and survival dependent on successful financing or deals.
Highly Stressed Balance SheetDeeply negative equity and debt materially exceeding assets create persistent solvency and refinancing risk. This structural weakness constrains strategic options, elevates cost of capital, and increases the likelihood that future financing will be dilutive or come with restrictive terms.
Consistent Cash Burn & Funding DependenceOperating and free cash flow remain meaningfully negative across years, requiring external funding to sustain R&D. This long-term dependence increases execution risk, makes timelines contingent on financing, and can lead to recurring dilution or constrained program choices.
Resverlogix News
0VF9 FAQ
What was Resverlogix Corp. J’s price range in the past 12 months?
Resverlogix Corp. J lowest share price was C$0.10 and its highest was C$0.13 in the past 12 months.
What is Resverlogix Corp. J’s market cap?
Resverlogix Corp. J’s market cap is C$32.67M.
When is Resverlogix Corp. J’s upcoming earnings report date?
Resverlogix Corp. J’s upcoming earnings report date is Aug 19, 2026 which is in 12 days.
How were Resverlogix Corp. J’s earnings last quarter?
Currently, no data Available
Is Resverlogix Corp. J overvalued?
According to Wall Street analysts Resverlogix Corp. J’s price is currently Overvalued.
Does Resverlogix Corp. J pay dividends?
Resverlogix Corp. J does not currently pay dividends.
What is Resverlogix Corp. J’s EPS estimate?
Resverlogix Corp. J’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Resverlogix Corp. J have?
Resverlogix Corp. J has 343,916,100 shares outstanding.
What happened to Resverlogix Corp. J’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Resverlogix Corp. J?
Currently, no hedge funds are holding shares in GB:0VF9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Resverlogix Corp. J
Resverlogix Corporation is a biotechnology firm currently in advanced clinical development, concentrating on developing treatments for illnesses where existing medical solutions are inadequate. The company's leading therapeutic compound is apabetalone (RVX-208), a selective small molecule designed to inhibit bromodomain and extra-terminal proteins. This compound is presently undergoing pivotal Phase III clinical trials for patients afflicted with conditions such as cardiovascular disease, diabetes, various stages of kidney disease (including end-stage renal disease), and neurodegenerative disorders. Furthermore, Resverlogix Corp. has forged an alliance with Eversana Life Science Services, LLC to support the forthcoming commercial rollout of apabetalone as a treatment for COVID-19 across the United States and Canada. The company's main office is located in Calgary, Canada.
Technical Analysis
XORTX Therapeutics Inc
―
BriaCell Therapeutics
―
Microbix Biosystms
―
Devonian Health Group
―
Thiogenesis Therapeutics Corp
―